Cocrystal Pharma (COCP) Cash & Equivalents (2010 - 2026)

Cocrystal Pharma has reported Cash & Equivalents for 17 years, with the latest figure at $4.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 31.96% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 31.96% YoY) and the FY2025 annual result came in at $7.1 million, down 28.54% from the prior year.
• Cash & Equivalents eased to $4.8 million in Q1 2026 per COCP's latest filing, from $7.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $54.8 million in Q1 2022 and troughed at $75000.0 in Q2 2022.
• A 5-year average of $16.2 million and a median of $9.9 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 99.89% in 2022, then jumped 43125.33% in 2023.
• Over 5 years, Cash & Equivalents stood at $37.2 million in 2022, then slipped by 28.99% to $26.4 million in 2023, then sank by 62.41% to $9.9 million in 2024, then declined by 28.54% to $7.1 million in 2025, then plunged by 32.96% to $4.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.8 million, $7.1 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.